These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1137 related items for PubMed ID: 27999210

  • 1. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E, Pratt S, Blosser W, Dowless M, Simpson N, Yuan XJ, Jaken S, Manro J, Stephens J, Zhang Y, Huber L, Peng SB, Stancato LF.
    Oncotarget; 2017 Feb 07; 8(6):9251-9266. PubMed ID: 27999210
    [Abstract] [Full Text] [Related]

  • 2. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
    Chen SH, Gong X, Zhang Y, Van Horn RD, Yin T, Huber L, Burke TF, Manro J, Iversen PW, Wu W, Bhagwat SV, Beckmann RP, Tiu RV, Buchanan SG, Peng SB.
    Oncogene; 2018 Feb 08; 37(6):821-832. PubMed ID: 29059158
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
    Peng SB, Henry JR, Kaufman MD, Lu WP, Smith BD, Vogeti S, Rutkoski TJ, Wise S, Chun L, Zhang Y, Van Horn RD, Yin T, Zhang X, Yadav V, Chen SH, Gong X, Ma X, Webster Y, Buchanan S, Mochalkin I, Huber L, Kays L, Donoho GP, Walgren J, McCann D, Patel P, Conti I, Plowman GD, Starling JJ, Flynn DL.
    Cancer Cell; 2015 Sep 14; 28(3):384-98. PubMed ID: 26343583
    [Abstract] [Full Text] [Related]

  • 4. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
    Zhao X, Wang X, Fang L, Lan C, Zheng X, Wang Y, Zhang Y, Han X, Liu S, Cheng K, Zhao Y, Shi J, Guo J, Hao J, Ren H, Nie G.
    Cancer Lett; 2017 Aug 28; 402():61-70. PubMed ID: 28576749
    [Abstract] [Full Text] [Related]

  • 5. Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.
    Henry JR, Kaufman MD, Peng SB, Ahn YM, Caldwell TM, Vogeti L, Telikepalli H, Lu WP, Hood MM, Rutkoski TJ, Smith BD, Vogeti S, Miller D, Wise SC, Chun L, Zhang X, Zhang Y, Kays L, Hipskind PA, Wrobleski AD, Lobb KL, Clay JM, Cohen JD, Walgren JL, McCann D, Patel P, Clawson DK, Guo S, Manglicmot D, Groshong C, Logan C, Starling JJ, Flynn DL.
    J Med Chem; 2015 May 28; 58(10):4165-79. PubMed ID: 25965804
    [Abstract] [Full Text] [Related]

  • 6. Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.
    Yao YM, Donoho GP, Iversen PW, Zhang Y, Van Horn RD, Forest A, Novosiadly RD, Webster YW, Ebert P, Bray S, Ting JC, Aggarwal A, Henry JR, Tiu RV, Plowman GD, Peng SB.
    Clin Cancer Res; 2017 Sep 15; 23(18):5547-5560. PubMed ID: 28611205
    [Abstract] [Full Text] [Related]

  • 7. Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.
    Chen SH, Zhang Y, Van Horn RD, Yin T, Buchanan S, Yadav V, Mochalkin I, Wong SS, Yue YG, Huber L, Conti I, Henry JR, Starling JJ, Plowman GD, Peng SB.
    Cancer Discov; 2016 Mar 15; 6(3):300-15. PubMed ID: 26732095
    [Abstract] [Full Text] [Related]

  • 8. BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells.
    Goulielmaki M, Koustas E, Moysidou E, Vlassi M, Sasazuki T, Shirasawa S, Zografos G, Oikonomou E, Pintzas A.
    Oncotarget; 2016 Feb 23; 7(8):9188-221. PubMed ID: 26802026
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of Pan-RAF Inhibitor LY3009120 on Human Uveal Melanoma Cell Line 92-1.
    Gao YU, Wendt S, Krohn S, Alammar M, Junghanss C, Nolte I, Escobar HM.
    Anticancer Res; 2024 Sep 23; 44(9):3843-3848. PubMed ID: 39197916
    [Abstract] [Full Text] [Related]

  • 10. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAFV600E mutant cancer.
    Hong SP, Ahn SK.
    Life Sci; 2017 Aug 15; 183():37-44. PubMed ID: 28645859
    [Abstract] [Full Text] [Related]

  • 11. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J, Lee I, Han B, Park JO, Jang J, Park C, Kang WK.
    J Natl Cancer Inst; 2011 Apr 20; 103(8):674-88. PubMed ID: 21398618
    [Abstract] [Full Text] [Related]

  • 12. Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic BRAF Mutation.
    Miyauchi S, Shien K, Takeda T, Araki K, Nakata K, Miura A, Takahashi Y, Kurihara E, Ogoshi Y, Namba K, Suzawa K, Yamamoto H, Okazaki M, Soh J, Tomida S, Yamane M, Sakaguchi M, Toyooka S.
    Anticancer Res; 2020 May 20; 40(5):2667-2673. PubMed ID: 32366411
    [Abstract] [Full Text] [Related]

  • 13. Cross-Species Comparison of the Pan-RAF Inhibitor LY3009120's Anti-Tumor Effects in Equine, Canine, and Human Malignant Melanoma Cell Lines.
    Gao Y, Packeiser EM, Wendt S, Sekora A, Cavalleri JV, Pratscher B, Alammar M, Hühns M, Brenig B, Junghanss C, Nolte I, Murua Escobar H.
    Genes (Basel); 2024 Feb 03; 15(2):. PubMed ID: 38397192
    [Abstract] [Full Text] [Related]

  • 14. Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells.
    Song Q, Sun X, Guo H, Yu Q.
    Oncotarget; 2017 Jan 17; 8(3):5003-5015. PubMed ID: 28002807
    [Abstract] [Full Text] [Related]

  • 15. LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.
    Monaco KA, Delach S, Yuan J, Mishina Y, Fordjour P, Labrot E, McKay D, Guo R, Higgins S, Wang HQ, Liang J, Bui K, Green J, Aspesi P, Ambrose J, Mapa F, Griner L, Jaskelioff M, Fuller J, Crawford K, Pardee G, Widger S, Hammerman PS, Engelman JA, Stuart DD, Cooke VG, Caponigro G.
    Clin Cancer Res; 2021 Apr 01; 27(7):2061-2073. PubMed ID: 33355204
    [Abstract] [Full Text] [Related]

  • 16. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A.
    J Clin Oncol; 2008 Dec 10; 26(35):5705-12. PubMed ID: 19001320
    [Abstract] [Full Text] [Related]

  • 17. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
    Wang H, Quan H, Lou L.
    Biochem Biophys Res Commun; 2017 Jul 15; 489(1):14-20. PubMed ID: 28536078
    [Abstract] [Full Text] [Related]

  • 18. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
    Yang H, Higgins B, Kolinsky K, Packman K, Bradley WD, Lee RJ, Schostack K, Simcox ME, Kopetz S, Heimbrook D, Lestini B, Bollag G, Su F.
    Cancer Res; 2012 Feb 01; 72(3):779-89. PubMed ID: 22180495
    [Abstract] [Full Text] [Related]

  • 19. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
    Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, Godfrey JT, Nishimura K, Lynch KD, Mermel CH, Lockerman EL, Kalsy A, Gurski JM, Bahl S, Anderka K, Green LM, Lennon NJ, Huynh TG, Mino-Kenudson M, Getz G, Dias-Santagata D, Iafrate AJ, Engelman JA, Garraway LA, Corcoran RB.
    Cancer Discov; 2015 Apr 01; 5(4):358-67. PubMed ID: 25673644
    [Abstract] [Full Text] [Related]

  • 20. Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration.
    Mooz J, Oberoi-Khanuja TK, Harms GS, Wang W, Jaiswal BS, Seshagiri S, Tikkanen R, Rajalingam K.
    Sci Signal; 2014 Aug 05; 7(337):ra73. PubMed ID: 25097033
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.